These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
179 related articles for article (PubMed ID: 25144909)
61. Treatment of Young People With Antipsychotic Medications in the United States. Olfson M; King M; Schoenbaum M JAMA Psychiatry; 2015 Sep; 72(9):867-74. PubMed ID: 26132724 [TBL] [Abstract][Full Text] [Related]
62. The utilization of psychopharmacological treatment and medication adherence among Medicaid enrolled children and adolescents with bipolar depression. Bhowmik D; Aparasu RR; Rajan SS; Sherer JT; Ochoa-Perez M; Chen H J Affect Disord; 2013 Sep; 150(2):424-9. PubMed ID: 23747210 [TBL] [Abstract][Full Text] [Related]
63. Prescribing of antipsychotic medication in a medicaid population: use of polytherapy and off-label dosages. Kogut SJ; Yam F; Dufresne R J Manag Care Pharm; 2005; 11(1):17-24. PubMed ID: 15667230 [TBL] [Abstract][Full Text] [Related]
65. Psychotropic Prescriptions During the COVID-19 Pandemic Among U.S. Children and Adolescents Receiving Mental Health Services. Amill-Rosario A; Lee H; Zhang C; dosReis S J Child Adolesc Psychopharmacol; 2022 Sep; 32(7):408-414. PubMed ID: 36067121 [No Abstract] [Full Text] [Related]
66. Trends in prescription of psychotropic medications to children and adolescents in Australian primary care from 2011 to 2018. Klau J; Bernardo CO; Gonzalez-Chica DA; Raven M; Jureidini J Aust N Z J Psychiatry; 2022 Nov; 56(11):1477-1490. PubMed ID: 34963342 [TBL] [Abstract][Full Text] [Related]
68. Racial and Ethnic Differences in Antipsychotic Medication Use Among Children Enrolled in Medicaid. Cataife G; Weinberg DA Psychiatr Serv; 2015 Sep; 66(9):946-51. PubMed ID: 25975884 [TBL] [Abstract][Full Text] [Related]
69. National Patterns of Commonly Prescribed Psychotropic Medications to Young People. Sultan RS; Correll CU; Schoenbaum M; King M; Walkup JT; Olfson M J Child Adolesc Psychopharmacol; 2018 Apr; 28(3):158-165. PubMed ID: 29376743 [TBL] [Abstract][Full Text] [Related]
70. The unintended (and costly) effects due to the introduction of an unrestricted reimbursement policy for atypical antipsychotic medications in a Canadian public prescription drug program: 1996/97 to 2005/06. O'Reilly DJ; Goeree RA; Tarride JE; James C; Parfrey PS Can J Clin Pharmacol; 2009; 16(2):e346-59. PubMed ID: 19531813 [TBL] [Abstract][Full Text] [Related]
71. Prior authorization policies for selective cyclooxygenase-2 inhibitors in Medicaid: a policy review. Fischer MA; Cheng H; Schneeweiss S; Avorn J; Solomon DH Med Care; 2006 Jul; 44(7):658-63. PubMed ID: 16799360 [TBL] [Abstract][Full Text] [Related]
72. Antipsychotic Medication Use In Medicaid-Insured Children Decreased Substantially Between 2008 And 2016. Bushnell G; Lloyd J; Olfson M; Cook S; Das H; Crystal S Health Aff (Millwood); 2023 Jul; 42(7):973-980. PubMed ID: 37406239 [TBL] [Abstract][Full Text] [Related]
73. Systematic Review: System-wide Interventions to Monitor Pediatric Antipsychotic Prescribing and Promote Best Practice. Mackie TI; Schaefer AJ; Karpman HE; Lee SM; Bellonci C; Larson J J Am Acad Child Adolesc Psychiatry; 2021 Jan; 60(1):76-104.e7. PubMed ID: 32966838 [TBL] [Abstract][Full Text] [Related]
74. The impact of prior authorization on buprenorphine dose, relapse rates, and cost for Massachusetts Medicaid beneficiaries with opioid dependence. Clark RE; Baxter JD; Barton BA; Aweh G; O'Connell E; Fisher WH Health Serv Res; 2014 Dec; 49(6):1964-79. PubMed ID: 25040021 [TBL] [Abstract][Full Text] [Related]
75. Psychotropic Medication Prescribing: Youth in Foster Care Compared with Other Medicaid Enrollees. Keefe RJ; Cummings ADL; Smith AE; Greeley CS; Van Horne BS J Child Adolesc Psychopharmacol; 2023 May; 33(4):149-155. PubMed ID: 37204275 [No Abstract] [Full Text] [Related]
76. Changes in antipsychotic medication use after implementation of a Medicaid mental health carve-out in the US. Robst J Pharmacoeconomics; 2012 May; 30(5):387-96. PubMed ID: 22316397 [TBL] [Abstract][Full Text] [Related]
77. Medicaid's prior authorization program and access to atypical antipsychotic medications. Polinski JM; Wang PS; Fischer MA Health Aff (Millwood); 2007; 26(3):750-60. PubMed ID: 17485754 [TBL] [Abstract][Full Text] [Related]
78. Metabolic testing rates in 3 state Medicaid programs after FDA warnings and ADA/APA recommendations for second-generation antipsychotic drugs. Morrato EH; Druss B; Hartung DM; Valuck RJ; Allen R; Campagna E; Newcomer JW Arch Gen Psychiatry; 2010 Jan; 67(1):17-24. PubMed ID: 20048219 [TBL] [Abstract][Full Text] [Related]
79. Use of atypical antipsychotic drugs for schizophrenia in Maine Medicaid following a policy change. Soumerai SB; Zhang F; Ross-Degnan D; Ball DE; LeCates RF; Law MR; Hughes TE; Chapman D; Adams AS Health Aff (Millwood); 2008; 27(3):w185-95. PubMed ID: 18381404 [TBL] [Abstract][Full Text] [Related]
80. High-cost use of second-generation antipsychotics under California's Medicaid program. Stahl SM; Grady MM Psychiatr Serv; 2006 Jan; 57(1):127-9. PubMed ID: 16399974 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]